Introduction
In as eries of precedentp ublications we and others have demonstrated that the cancerostatic/cancerotoxic activity of pyrimidine ß-d-ribonucleoside antimetabolites such as 5-fluorouridine and 6-azauridine towards different human tumor cell lines [1, 2] as well as neurobiological [3] and antiviral activities [4, 5] can be significantly improved by lipophilization. Also, regular, canonical pyrimidine ß-d-ribonucleosides such as uridine and 5-methyluridine acquireasurprisingly high antitumor in vitro activity upon covalenth ydrophobization. [6, 7] The positioning and type of the lipophilicr esidues are hereby of decisive importance.I th as been shown that, in particular,t he introduction of an ethyl levulinate group at the O-2',3'-hydroxyls in form of ac yclic ketal and, additionally,afarnesyl sesquiterpene moiety at N(3) leads to compounds with significant activity. [2] In this manuscript, we extend our studyt op urine ß-d-ribonucleoside nucleolipids,p articularly to inosine and adenosine derivatives. Again, as electiono ft he compounds was tested with respect to the viability/survival of phorbol1 2-myristate 13-acetate (PMA)-differentiated humanT HP-1 macrophages when treated with these compounds. [2] Those which provedt o be nontoxic for the immune cellsw eret hen further tested on their cytostatic/cytotoxic in-vitro activity towards human astrocytoma/oligodendroglioma GOS-3 cells, as well as against rat malignant neuroectodermal BT4Ca cells.
Results and Discussion

Synthesis
Startingf rom adenosine (1) , its ethyl levulinate derivative 3 was prepared according to aw ell-known procedure (Scheme 1). [8] However,i nc ontrast to older publications, we found that this ketal formation resulted in the formation of ad iastereoisomeric mixture (1R)/(1S)w ith ar atio of about 10:1 in all cases.
Ketal formation of adenosine with nonadecan-10-one gave the nucleolipid 5.B oth O-2',3' ketals (3 and 5)w ere then submittedt oa ne nzymatic deamination using adenosined eaminase (from calf intestine). It could be clearly shown that compound 3 could be deaminated within 72 hy ielding the inosine We report on the synthesis of two series of canonical purine ß-d-ribonucleoside nucleolipids derived from inosine and adenosine, which have been characterizedb ye lemental analyses, electrospray ionization mass spectrometry (ESI MS) as well as by 1 Ha nd 13 CNMR, andp H-dependent UV/Vis spectroscopy.A selectionofthe novel nucleolipids with differentlipophilic moieties were first tested on their cytotoxic effect towardh uman macrophages. Compounds without as ignificant inhibitory effect on the viability of the macrophages were tested on their cytostatic/cytotoxic effect toward human astrocytoma/oligodendroglioma GOS-3 cells as well as against the rat malignant neuroectodermal BT4Ca cell line. In order to additionally investigate the potentialm olecular mechanisms involved in the cytotoxic effects of the derivatives on GOS-3 or BT4Ca cells, we evaluatedthe induction of apoptosis and observedthe particular activity of the nucleolipid ethyl 3-{4-hydroxymethyl-2-methyl-6-[6-oxo-1-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-1,6-dihydro-purin-9-yl]-tetrahydro-furo [3,4-d] [1, 3] dioxol-2-yl}propio-nate (8c)t oward both human and rat glioblastoma celll ines in vitro. derivative 4, [9] while 5 could not be deaminated to 6.T he latter was obtained by direct ketal formation of inosine (2) with nonadecan-10-one.
All novel compounds werecharacterized by elemental analyses, high-resolutione lectrospray ionization mass spectrometry (HR ESI MS) as well as by 1 Ha nd 13 CNMR, and pH-dependent UV/Vis spectroscopy.A ssignment of 13 CNMR resonances was made with the help of DEPT-135 as wella sb yg radient-selected homo-and heteronuclear correlation spectroscopy (Bruker pulse programs, 1 CNMR spectra,r evealed that compound 3 wasf ormed as ad iastereoisomeric (1R)/(1S)-mixture (for an example of the diastereoisomer structures, see Scheme 2), while the subsequentd eamination product 4 proved to be the diastereoisomerically almost pure (1R)derivative. This might be traced back to the following reasons: 1) It has been shown earlier that the enzymatic deamination of adenosine which has been ketalized at the 2',3'-O positionw ithu nsymmetrical ketones such as pentan-2-one [10] to the corresponding (1R)a nd (1S)2 ',3'-O-(1-methylbutylideScheme1.Stepwise lipophilization of adenosine (1) www.chemistryopen.org ne)adenosines occurs with significantly different MichaelisMenten kinetics;t he (1S)-configured ketal is deaminated at an 8.5-fold lower v max rate than the (1R)-configured isomer. [10] 2) The deaminationp roduct 4 was isolated by crystallization which might lead to ap referred precipitation of the corresponding (1R)p roduct. In contrast to this, ketal formation of inosine (2)w ith ethyl levulinate in the presence of triethylorthoformate [9, 11] leads to ad iastereoisomeric mixture of compound 4 [(1R):(1S) % 10:1] (Schemes 1a nd 3).
Interestingly,t he 13 CNMR spectrum of compound 4,p repared by the latter method, exhibits characteristically increasing Dd values [(1R)-(1S)] for the C(1'), C(4'), C(2'), and C(3')c arbons and as trongd ecrease again for C(5')( Figure1). The graph shown in Figure 1d emonstratesa lmost identical chemical shift differences of compound 4 as well as of the analogous compound 9
[12] -both adoptinga nanti-conformation at the Nglycosylicb ond.T he formation of an almoste quimolar mixture of (1R)a nd (1S)d iastereoisomers of ak etalf ormation reaction of inosine with 4-oxopentyl 4-methylbenzoate has been found already recently.
[12] It was corroborateda lso for analogous reactions with other nucleosides whichw ill be the subject of af orthcoming publication. The almosti dentical chemical shift differences, which have already been observed earlier for pyrimidine ß-d-ribonucleoside ketals [7] might be the result of the interworking of various CÀOa nd CÀCm agnetic anisotropy effects [13] of ketal moiety bonds ( Figure S1 in the Supporting Information),f or example of {C(acetal)ÀO} and {CH 2 (acetal)À CH 2 (C=O)} bonds, within (1R)-O-2',3'-[1-(2-carboxyethyl)ethyliden]adenosine. [14] .
Otherss uch as {C(acetal)ÀCH 2 (acetal)} anisotropy effectsmay be counterproductive.
In the following, we lipophilized the inosine nucleolipid 6 furthera tN (1) by farnesylation (dimethylformamide [DMF], K 2 CO 3 ) [15] and obtained compound 7.I tc ould be shown that the alkylation occurs without 5'-OH protection which might be substantially advantageous for an antitumor activity as the latter requires probably an intracellular phosphorylationo ft he 5'-OH group. Because it had been recently shown that al ipophilization of pyrimidine ß-d-ribonucleosides at the O-2',3' position as well as at N(3) of the pyrimidine base leads to nucleolipids with ap ronounced and selectivec ytostatic/cytotoxic in vitro activity toward varioush uman tumor cell lines, [2] we now converted also the inosine derivative 4 [pure (1R)-diastereoisomer,p reparedb ye nzymatic deamination from compound 3] to the corresponding N(1)-prenylated inosine nucleolipids 8a-c.I nt he case of the preparation of compounds 8a,b by-products, such as probably formed O-alkylated compounds, were chromatographically removed and not furtherc haracterized. Only in the case of the farnesylation of compound 4,t he reaction was studied in more detail;itw as performed at two different temperatures:1 )Atr oom temperature (20 8C), the alkylation afforded the N(1)-prenylated derivatives 8c (kinetic reaction control, see Experimental Section). 2) Alkylation at already slightly elevated temperatures (40-55 8C), however,g ave, after work-up, the N(1)-as well as further O(4)-prenylated derivatives such as 8d (thermodynamic reaction control)and another one, the structure of whichp roved to be more complicated. The general structure of the O-alkylated derivatives was corroborated by pH-dependentU V/Vis spectroscopy.T entatively,w e postulate that the O(6)-farnesylated nucleolipid 8d reacts with Next, we alkylated the adenosine nucleolipid 3 [8] with three different prenyl bromides and obtained the corresponding N(1)-alkylated salts 13 a-c (Scheme 2). These were submitted to Dimroth rearrangements [16, 17] with an aqueous dimethylamine solution [18] which yieldedt he adenosine nucleolipids 14 a-c.B yt his way,w ewere able to synthesize chain-extended analogues of the nucleoside antimetabolite N(6)-isopentenyladenosine {= N 6 -(D 2 -isopentenyl)adenosine} [19] carrying additionally an O-2',3'-ethyllevulinate ketal group withouts aponification of the ester.Ina ne arlier publication we have reported the synthesis of an N(6)-isopentenyladenosined erivativew ith an O-2',3'-levulinate moiety using 1 n aq NaOH. [20] All compounds were characterizedb yH RE SI MS, elemental analyses, as well as by 1 Ha nd 13 CNMR and UV/Vis spectroscopy. 
Lipophilicproperties of purine ß-d-ribonucleosides and their nucleolipids
Applyingt he ALOGPS v.3.01 program, [21, 22] the 10 LogP ow values of the nucleolipids, as well as of their precursor molecules, were calculated;f or this purpose we used the eadmet.com/de/ physprop.php site with ePhysChem that contains the program mentioned. The resultsa re shown in Figure 2A ,B. The figures clearly demonstratet he possibility of af ine tuning of the compounds' lipophilicity by the introduction of stepwisee longated prenyl side chains to both adenosine and inosine.
In addition to 10 LogP ow calculations, we have also measured such data experimentally for those four compounds which have been tested biologically (see Experimental Section). A comparison of calculated and experimental data can be seen in Ta ble 1.
Scheme4.Side reactionso ccuring upon farnesylation of inosin-O-2',3'-ketal 4. Reagentsand conditions: a) farnesyl bromide, K 2 CO 3 ,DMF,rt, 24 h, 57 %; b) farnesyl bromide, K 2 CO 3 ,DMF,3 08C, 30 min,t hen r.t.,24h;c)excesso ffarnesyl bromide, 24 h, 55 8C, 12:3 7%.R EL:ribosylethyllevulinate. Table 1 . Translation of plain compoundn umbers into the NS/NL-nomenclature. [23] Compound numbers NS/NLcode [a] Compound numbers
NL_5.3.0.0 13 a NL_5. [a] Accordingt oR ef. [23] .N.a.n.: not an umber. 
Biological results
Using an in vitro model to differentiate between anticancer properties and sidee ffects, we tested the cytotoxic effects on the viability of PMA-differentiated humanT HP-1 macrophages after treatment for 48 h. At concentrations of 6.25, 12.5, 25, or 50 mm 5-fluorouridine, there was as ignificant inhibition of the viability/survival by 11.9 %( p < 0.001), 8.4 %( p < 0.05), 13.7 % (p < 0.001), 12.14 %( p < 0.05) compared with negative control ( Figure 3 ). The purine derivative 8c did not exhibit any significant inhibitory effect on viability/survival of THP-1 macrophages ( Figure 3 ). At ac oncentration of 50 mm, the derivatives 5 and 6 [23] revealed significantly (p < 0.001) cytotoxic effects of 93.3 % and 86.5 %; additionally,t he derivative 5 significantly (p < 0.001) showedc ytotoxic effects of 69.9 %a t2 5mm,i nc omparison with the control ( Figure 3 ). Because the derivative 8c revealed no or only marginal cytotoxic effects on differentiated human THP-1 macrophages, the effects of this substance-in comparison with the positivec ontrol (5-fluorouridine)-was tested in human astrocytoma/oligodendroglioma GOS-3 and rat malignant neuroectodermal BT4Ca cells. Incubation (48 h) of the human astrocytoma/oligodendroglioma GOS-3 cells with 5-fluorouridine, at concentrations of 1.56, 3.12, 6.25, 12.5, 25, or 50 mm,r esulted in significant (p < 0.001) 45.5, 54.4, 51.6, 54.0, 53.7, and5 9.0 %i nhibitions of the viability/survival, whereas incubation with derivative 8c at 25 mm and 50 mm significantly inhibited the viability/survival by 28.1 %( p < 0.01) and 91.2 %( p < 0.001), in comparison with the control (Figure 4) .
Moreover,i ncubation (48 h) of the rat malignant neuroectodermal BT4Ca cells with 5-fluorouridine (1.56, 3.12, 6.25, 12.5, 25, or 50 mm)r esulted in significant (p < 0.001), 60.3, 58.7, 65.1, 59.5, 58.8, and 68.1 %i nhibitions of the viability/survival when compared with the control.A tc oncentrationso f2 5mm and 50 mm,t he derivative 8c significantly (p < 0.001) inhibited the viability/survival by 58.6 %a nd 81.8 %, and at ac oncentration of 12.5 mm, viability/survival was (not significantly) inhibited by 11.9 %, in comparison with the control ( Figure 5 ).
In order to investigate additionally the potential molecular mechanisms involvedi nt he cytotoxic effectso ft he derivatives on GOS-3 or BT4Ca cells, induction of apoptosis wase valuated. At ac oncentration of 50 mm, the derivative 5-fluorouridine sig- Additional investigations of the protein expression (western blot) of the ubiquitin-binding autophagic adaptor p62/SQSMT1 (hereafter p62) showedasignificant (p < 0.01) activation being 260 %h igher than the negative control (100 %) after treatment with 25 mm 8c ( Figure 8A ,C). Proliferating cell nuclear antigen (PCNA) expression showed as ignificant (p < 0.05) inhibition by 84.4 %o r7 3.1 %, which was, however,n ot significant after treatment with 12.5 mm or 25 mm of 5-fluorouridine, respectively ( Figure 8A,C) . Whereas treatment with 12.5 mm and 25 mm 8c significantly (p < 0.01) inhibited the PCNA expression in GOS-3 cells by 76.6 %a nd 96.8 % ( Figure 8B,C) . Furthermore, treatment of BT4Ca cells with 12.5 mm 5-fluorouridine showed as ignificant (p < 0.01) 67.7 %i nhibition, whereas the effect of 25 mm was nonsignificant when compared with the control. Treatmentw ith 12.5 mm of 8c showed as ignificant (p < 0.01) 50.2 %i nhibition, but 25 mm increased significantly (p < 0.05) 49.5 %t he protein expression of p62/SQSMT1 when compared with the control (Figure 9A,C) . Furthermore, after treatment of 
Experimental Section Nomenclature
For the general numbering of nucleosides and nucleolipids, an ovel denomination system was developed which allows an easy comparison of compound data among the various publications of our groups and which is disclosed in ref. [23] .M oreover,i tw as deposited sustainably in the repository of the library of the University 
Chemistry
General Remarks: All chemicals were purchased from SigmaAldrich (Deisenhofen, Germany) or TCI-Europe (Zwijndrecht, Belgium). Solvents were of laboratory grade and were distilled before use. Column chromatography was performed on silica gel 60. Thinlayer chromatrography (TLC) was performed using aluminum sheets and silica gel 60 F 254 ;0 .2 mm layer (Merck, Germany). NMR spectra ( 1 H, 13 C, DEPT-135) were obtained using an AMX-500 instrument (Bruker,R heinstetten, Germany); 1 H: 500.14 MHz, 12.000, DEPT-135:5 .000. ESI MS was performed using aB ruker Daltronics Esquire HCT instrument (Bruker Daltronics, Leipzig, Germany);i onization was performed with a2%a q. formic acid (HCOOH) solution. UV/VIs spectra were obtained using aCary 1E spectrophotometer (Varian, Darmstadt, Germany). Compound samples of about 1mgw ere dissolved either in MeOH or an appropriate buffer solution (pH 3, 7, or 9, 100 mL each). Aliquots of 1mLo ft he fully dissolved compounds (warming, ultrasonication) were subjected to UV/Vis spectrometry in MT4 quartz cuvettes (Hellma, Darmstadt, Germany). Elemental analyses (C, H, N) were performed on aV arioMICRO instrument (Fa. Elementar,H anau, Germany). 10 LogP OW values were calculated using the http://eadmet.com/de/ physprop.php website with ePhysChem that contains ALOGPS v.3.0. Experimental determination of 10 LogP ow values of compounds were performed as follows:s amples of compounds 5-fluorouridine (NS_ 4.0.0.0), 6 (NL_5.3.0.0), 8c (NL_6.1. 1 3.0), 6 (NL_6.3.0.0) (2 mg, each) were dissolved in ah eterogenic mixture of n-butanol (25 mL) and H 2 O( 25 mL) by ultrasonication (10 min) under slightly warming. After separation of the layers from each phase aliquots of 1mL were withdrawn, and their UV spectra were run in 1cmquartz cuvettes. From the ratio of maximal extinctions of both layers at l max , the corresponding 10 LogP ow values were calculated and compared with increment-based calculations (Table 2) .
Generalsynthetic methods
The complete characterization data for all synthesized compounds mentioned below can be found in the Supporting Information.
Ethyl 3-[4-(6-amino-purin-9-yl)-6-hydroxymethyl-2-methyl-tetrahydro-furo [3,4-d] [1, 3] dioxol-2-yl]-propionate (3, NL_5.1.0.0, [8] diastereoisomeric mixture):T he compound was prepared following ap reviously described procedure, [8] but with slight modifications and supported by further analytical data. To as olution of anhydrous adenosine (1,N S_5.0.0.0, [23] 1.38 g, 5mmol) in dry and 
-propionate (4, NL_ 6.1.0.0 [9, 11, 23] ): A) By enzymatic deamination of 3:C ompound 3 (0.94 g, 2.39 mmol) was dissolved in H 2 O( 27 mL), and adenosine deaminase (90 units, calf intestine)-dissolved in 0.9 mL of glycerol-was added. The reaction mixture was stirred at ambient temperature for 72 h( TLC monitoring). The resulting solution was evaporated on ar otary evaporator,l eaving colorless crystals of the title compound as pure (1R)-4 diastereoisomer (0.94 g, 2.39 mmol, 100 %). B) By Direct Ketal Formation of Inosine:A nhydrous inosine (2,1 .0 g; 3.73 mmol) was dissolved in dry DMF (18 mL). Then, ethyl levulinate (1.05 mL;7 .41 mmol), triethylorthoformate (0.92 mL; 5.60 mmol), and 4 m HCl in 1,4-dioxane (3.5 mL) were added, and the reaction mixture was stirred for 26 ha tr t. The reaction mixture was partitioned between CH 2 Cl 2 (175 mL) and as aturated conc. aq. NaHCO 3 -solution (5 mL). The aqueous phase was washed twice with CH 2 Cl 2 (80 mL, each). The combined organic layers were evaporated and repeatedly co-evaporated from CH 2 Cl 2 to remove residual DMF.T he oily residue was dried in high vacuum o/n at 40 8Ca nd subsequently purified by column chromatography (SiO 2 60 H, column:6 .5 14cm; CH 2 Cl 2 /MeOH;8 5:15; v/v). From the main zone, the title compound was isolated as aw hite powder (diastereoisomeric mixture, 1.108 g, 2.81 mmol, 75 %). The material proved to be identical with an authentic sample in all respects, except for the NMR data. [9, 11] 6-(6-Amino-purin-9-yl)-2,2-dinonyl-tetrahydro-furo [3,4- [23] ):T oasolution of anhydrous adenosine (1.0 g, 3.74 mmol) in dry DMF (15 mL) nonadecan-10-one (2.1 g, 7.48 mmol), triethylorthoformate (1.0 g, 5.61 mmol), and 4 m HCl in 1,4-dioxane (3.4 mL) were added. The reaction mixture was stirred for 48 ha tr ta nd then partitioned between CH 2 Cl 2 (175 mL) and as at. aq. NaHCO 3 solution (50 mL). The organic layer was washed with H 2 O(3100 mL), and the combined aqueous layers were re-extracted with CH 2 Cl 2 (25 mL). The combined organic phases were evaporated, and the oily residue was dried in high vacuum overnight and then submitted to column chromatography (SiO 2 60 H, column:6 12cm, CH 2 Cl 2 /MeOH 87:13). Evaporation of the main zone gave the title compound as acolorless oil (776 mg, 1.46 mmol, 39 %).
-dihydro-purin-6-one (6, NL_6.3.0.0):T oas olution of anhydrous inosine (2,1.0 g, 3.72 mmol) in dry DMF (15 mL), nonadecan-10-one (2.1 g, 7.44 mmol), triethylorthoformate (1.0 g, 5.58 mmol), and 4 m HCl in 1,4-dioxane (3.4 mL) were added. The reaction mixture was stirred for 48 ha ta mbient temperature under exclusion of moisture. Then, the mixture was partitioned between CH 2 Cl 2 (350 mL) and as aturated aqueous NaHCO 3 solution (50 mL). The organic layer was washed with H 2 O( 3100 mL), and the combined aqueous phases were re-extracted with CH 2 Cl 2 (2 25 mL). The combined organic layers were dried (Na 2 SO 4 ), filtered, and evaporated. The residue was dried o/n in high vacuum and then submitted to column chromatography (SiO 2 60 H, column:6 14 cm, CH 2 Cl 2 /MeOH 9:1). Evaporation of the main zone afforded the title compound as ac olorless oil (700 mg, 1.314 mmol, 35 %). 1-(3,7,1 )-trimethyl-dodeca-2,6,10-trienyl)-1,9-dihydro-purin-6-one (7, NL_6.3.3.0):T oasolution of compound 6 (593 mg, 1.113 mmol) in dry DMF (6 mL), K 2 CO 3 ,( 390 mg, 2.88 mmol) was added, and the suspension was stirred for 30 min at ambient temperature. Thereupon, farnesyl bromide (0.35 mL, 1.17 mmol) was added dropwise under an N 2 atmosphere while stirring. After 24 h, K 2 CO 3 was filtered off and washed repeatedly with CH 2 Cl 2 (2 25mL). The filtrate and washings were evaporated on ar otary evaporator;t he resulting oil was dried in high vacuum for 24 h. The residue was submitted to column chromatography (SiO 2 60 H, column:6 12cm, CH 2 Cl 2 /MeOH 97:3). Evaporation of the main zone afforded the title compound as ac olorless oil (499.2 mg, 0.677 mmol, 61 %). [23] ):T oas olution of anhydrous (dried at 80 8Co vernight), stereochemically pure compound (1R)-4 (0.35 g, 0.89 mmol) in dry DMF (10 mL), dry K 2 CO 3 (0.49 g, 3.55 mmol) was added. The suspension was stirred for 30 min at ambient temperature. Subsequently,i sopentenyl bromide (0.95 mmol) was added dropwise under Ar atmosphere and under exclusion of light and moisture. The reaction mixture was stirred for 60 ha trt. The salt was then filtered off and washed with CH 2 Cl 2 (2 25mL);t he filtrate and washings were combined and partitioned between H 2 O( 30 mL) and CH 2 Cl 2 (40 mL) in as eparation funnel. The organic phase was pooled, and the aqueous was washed with CH 2 Cl 2 (2 25mL). The combined organic layers were dried (Na 2 SO 4 ), filtered, and evaporated on ar otary evaporator.R esidual DMF was removed by repeated co-evaporation with CH 2 Cl 2 and subsequent drying in high vacuum. Column chromatography (SiO 2 60 H, column:5 6.5 cm, CH 2 Cl 2 /MeOH 98:2) gave the title compound as acolorless oil (200 mg, 0.43 mmol, 48 %) 2.0, [23] ):T oasolution of anhydrous (dried at 80 8Co vernight), stereochemically pure compound (1R)-4 (0.35 g, 0.89 mmol) in dry DMF (10 mL), dry K 2 CO 3 (0.49 g, 3.55 mmol) was added. The suspension was stirred for 30 min at ambient temperature. Subsequently,g eranyl bromide (0.95 mmol) was added dropwise under Ar atmosphere and under exclusion of light and moisture. The reaction mixture was stirred for 60 ha tr t. Then, the salt was filtered off and washed with CH 2 Cl 2 (2 25mL);t he filtrate and washings were combined and 3.0, [23] ):T oasolution of anhydrous, stereochemically pure compound (1R)-4 (0.2 g, 0.51 mmol) in dry DMF (3 mL), K 2 CO 3 (178 mg, 1.32 mmol) was added. The suspension was stirred at ambient temperature for 30 min. Then farnesyl bromide (0.16 mL, 0.56 mmol) was added dropwise under Ar atmosphere. The reaction mixture was stirred for 24 ha tr tu nder exclusion of light and moisture. Thereupon, the suspension was filtered, and the salt was washed repeatedly with CH 2 Cl 2 (2 25mL). Filtrate and washings were evaporated on ar otary evaporator,a nd the oily residue was dried in high vacuum. The raw product was purified by column chromatography (SiO 2 60 H, column:6 .5 11cm, CH 2 Cl 2 /MeOH 97:3). Evaporation of the main zone gave the title compound as ac olorless oil (175.1 mg, 0.29 mmol, 57 %).
Repetition of the formerly described experiment at elevated temperatures yielding 8c and 9-{2,3-O[(1R)-4-ethoxy-1-methyl-4-oxobutylidene]-ß-d-ribofuranosyl}-6-{[(2E,6E,9E,13E,17E)-3,7,11,11,14,18,22-heptamethyltricosa-2,6,9,13,17,21-hexaen-1-yl]oxy}-9H-purine (12, via nonisolated 8d):T oas olution of anhydrous, stereochemically pure compound (1R)-4 (0.15 g, 0.51 mmol) in dry DMF (4.8 mL), K 2 CO 3 (140 mg, 1.32 mmol) was added. The suspension was heated to 50 8Cf or 30 min and then cooled to 40 8C. Then, farnesyl bromide (0.12 mL;0 .42 mmol) was added dropwise stirred at ambient temperature for 30 min. Subsequently, as econd portion of farnesyl bromide (0.16 mL, 0.38 mmol) was added dropwise under Ar atmosphere. The reaction mixture was stirred for another 24 ha tr tu nder exclusion of light and moisture. Then, CH 2 Cl 2 (6 mL) was added;t he suspension was filtered, and the salt was washed repeatedly with CH 2 Cl 2 (2 25mL). Filtrate and washings were evaporated on ar otary evaporator,a nd the oily residue was dried in high vacuum. The raw product was purified by column chromatography (SiO 2 60 H, column:6 .5 10cm; 1. main zone, CH 2 Cl 2 /MeOH;9 4:6; v/v;2 .main zone, MeOH, 0.3 bar). From the faster-migrating main zone, compound 8c was isolated as acolorless oil (128 mg, 0.214 mmol, 56 %). The compound was identical with an authentic sample of compound 8c in all other respects ( 1 HNMR, 13 CNMR, HR ESI MS). From the slower-migrating zone, the title compound 12 was isolated as ac olorless oil (115 mg, 0.142 mmol, 37 %).
General procedure for the prenylation of the adenosine-O-2',3'-ketal 3:A nhydrous compound 3 (0.59 g, 1.5 mmol) was dissolved in anhydrous and amine-free DMF (4 mL). To the solution was added BaCO 3 (0.89 g, 4.5 mmol). Under Ar atmosphere, isopentenyl bromide, geranyl bromide or farnesyl bromide were added dropwise (1.95 mmol each). The reaction mixtures were stirred o/n at rt under exclusion of moisture and light. Subsequently,t he salt was removed by filtration through aC elite pad. The corresponding filtrates were evaporated on ar otary evaporator,a nd the residues were then dried in high vacuum to give aslightly red foam. Trituration with CH 2 Cl 2 (50 mL) afforded an off-white solid which was isolated by filtration. Purification was performed by column chromatography (SiO 2 60 H, column:58.5 cm or 6.5 10.5 cm, respectively,CH 2 Cl 2 /MeOH 9:1or9 5:5, respectively). Evaporation of the corresponding main zone gave the N(1)-prenylated salts 9a-c. [23] ):T he product was obtained as aw hite solid (0.44 g, 0.95 mmol, 63 %).
2.0, [23] ):T he product was obtained as as lightly yellowish solid (0.78 g, 1.48 mmol, 58 %).
,11-trimethyl-dodeca-2,6,10-trienyl)-9H-purin-1-ium bromide (9 c, NL_ 5.1. 3.0, [23] ):T he product was obtained as as lightly orange oil (0.98 g, 1.64 mmol, 67 %).
General Procedure for the Dimroth rearrangements of compounds 9a-c: [16, 17] Compounds 9a-c (0.7 mmol, each) were suspended in Me 2 NH-MeOH (1 m,4 .5 mL) and stirred for 20 ha ta mbient temperature (TLC monitoring). Subsequently,t he corresponding reaction mixtures, containing compounds 10 a, 10 b,o r10 c, were concentrated on ar otary evaporator and then in high vacuum. The residues were purified by column chromatography (SiO 2 60 H, columns:57 cm, 6.5 12.5 cm, and 6. 2.0, [23] ):T he product was obtained as acolorless oil (0.18 g, 0.34 mmol, 23 %). 3.0, [23] ):T he product was obtained as ac olorless oil (0.47 g, 0.62 mmol, 38 %).
Biological methods
Cell lines and culture conditions:I nvitro experiments were performed using the human astrocytoma/oligodendroglioma GOS-3 cells (DSMZ GmbH, Braunschweig, Germany), the rat malignant neuro-ectodermal BT4Ca cells (a kind gift from Dr.N adine John, Hannover Medical School, Hannover,G ermany), as well as the human acute monocytic leukemia cell line THP-1 (DSMZ GmbH, Braunschweig, Germany). The cells were cultured in 90 %R PMI 1640 medium supplemented with 10 %f etal bovine serum (FBS), 100 UmL À1 penicillin, and 0.1 mg mL À1 streptomycin, and were maintained at 37 8Ci nahumidified atmosphere (5 %C O 2 ,9 5% air) as described earlier. [1, 2] Determination of viability/survival of 5-fluorouridine and derivatives:9 6-well plates (BD Falcon, Becton Dickinson GmbH, Heidelberg, Germany) were seeded with 1.5 10 4 GOS-3, 510 3 BT4Ca, or 310 4 THP-1 cells. After 24 h, the medium was changed and different concentrations of 5-fluorouridine or its derivatives 5, 6, 8c, were tested at concentrations of 1.56, 3.12, 6.25, 12.5, 25, or 50 mm. After incubation for 48 h, viability/cytotoxicity was measured using PrestoBlue reagent (Invitrogen-Life Te chnologies GmbH, Darmstadt, Germany) as described earlier. [1, 2] PrestoBlue was added to the cells into the culture medium and 30 min, 1h,2h, or 3hafter addition of PrestoBlue ,t he optical density (OD) was measured at 570 nm and 600 nm (as reference) with aS UNRISE ELISA-reader (Tecan, Salzburg, Austria). Results are expressed in %survival (OD 570/ 600 nm of samples 1 00 /O D5 70/600 nm of control without substances). As control (100 %v iability = 0% cytotoxicity), cells were cultured with medium alone. To evaluate the cytotoxic effect on macrophages, this procedure was repeated with 510 3 per well of phorbol-12-myristate-13-acetate (PMA;1 00 ng mL À1 )-differentiated (48 h) human THP-1 macrophages, which were treated (48 h) with different concentrations of the substances under test.
Apoptosis assay:H uman GOS-3 cells or rat BT4Ca were seeded in 96-well plates at ad ensity of 1.5 10 4 and 510 3 per well, respectively.A fter 24 h, the medium was changed, and the substances under test were added at various concentrations as indicated. Apoptotic cells were identified by YO-PRO-1 (1 mm)incombination with the Hoechst 33342 nuclear staining dye (5 mg mL À1 ;M obitec Company,G çttingen, Germany). The total number of cells (Hoechst 33342 + nuclei)a nd apoptotic cells (YO-PRO-1 + nuclei)w as counted using an inverse fluorescence microscope Eclipse TS100 (Nikon GmbH, Düsseldorf, Germany) equipped with ac amera AxioCam MRc (Carl Zeiss Microscopy GmbH, Gçttingen, Germany) and acomputer-assisted morphometry system AxioVision 4( Carl Zeiss Microscopy GmbH), and the percentage of apoptotic cells to the total cells was then calculated. Additionally the %o ft otal cell count after 48 ht reatment was calculated using the total number of cells containing Hoechst 33342 + nuclei, considering the negative control without treatment as 100 %.
